Purpose: To develop a simple, rapid
and sensitive high performance liquid chromatography (HPLC)
method for the determination of cefadroxil monohydrate
in human plasma.
Methods: Schimadzu HPLC with LC
solution software was used with Waters Spherisorb, C18
(5 µm, 150mm × 4.5mm) column. The mobile phase was
sodium dihydrogen phosphate buffer pH 4.0 and methanol
in a ratio of 96:4. Flow rate was 1.5 ml/min and
injection volume was 100 µl. Peak response was detected
at 260 nm.
Results: System suitability results
revealed that the coefficient of variation (CV) for
retention time, peak response, tailing factor and
resolution of six replicate injections was < 3 %. The
method was selective to determine cefadroxil in plasma
because there was no peak interference of plasma with
cefadroxil at its retention time (7.792 min). Linearity
was in the range of 0.5 - 30 µg/ml with slope and
intercept of 41694.53 and 22614.87, respectively (R2
= 0.9953). Limit of detection (LOD) and lower limit of
quantification (LLOQ) of the method were 0.03 and 0.06
µg/ml, respectively. Absolute recovery of cefadroxil
from plasma was in the range 71 - 90.4 %, while
inter-day and intra-day analysis showed satisfactory
precision and accuracy; thus, the method was
reproducible with the range of CV, i.e., 0.35 - 4.01 and
1.88 - 7.9 % for interday and intraday precision,
respectively.
Conclusion: The developed method being
simple, rapid, reproducible can be suitably employed in
pharmacokinetic and bioequivalence studies of cefadroxil
monohydrate.
Keywords: Validation, Cefadroxil
monohydrate, Human plasma, Pharmacokinetics
Bioequivalence